Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study
Rachelle Buchbinder, Sharon Van Doornum, Margaret Staples, Marissa Lassere, Lyn March
BMC Musculoskeletal Disorders | BIOMED CENTRAL LTD | Published : 2015
Awarded by Commonwealth Government of Australia National Health & Medical Research Council (NHMRC)
ARAD has received support from the Commonwealth Government of Australia National Health & Medical Research Council (NHMRC) Enabling Grant (ID 384330), Monash University, the Australian Rheumatology Association, Abbott Australia, Pfizer Australia, Janssen Australia, Sanofi Aventis, Amgen, Wyeth, Schering-Plough and Roche. This analysis was supported by an Arthritis Australia grant-in-aid and a University of Melbourne grant-in-aid. RB is supported by an Australian NHMRC Senior Principal Research Fellowship.